9月29日，深圳市政府新闻办召开"推动传统产业向'新'向'智' 加快建设现代化产业体系"新闻发布会。深 圳市工业和信息化局副局长平原介绍了深圳市推进传统产业优化升级的工作背景、亮点成绩和主要举 措，并与市商务局副局长周明武、市市场监管局副局长李军、罗湖区副区长时冬昕、龙华区副区长赵妍 妍就相关问题回答了记者提问。 积淀深厚：传统产业交出亮眼成绩单 尽管战略性新兴产业与未来产业光彩夺目，深圳的传统产业同样底蕴深厚，成果丰硕。深圳市工业和信 息化局副局长平原在发布会上表示，在高端女装领域，深圳培育了珂莱蒂尔、歌力思（603808）、影 儿、玛丝菲尔、卡尔丹顿等一批领军品牌，以及蕉内、蕉下等新锐力量，其品牌数量、市场占有率、上 市企业数量均位居全国前列。黄金珠宝行业年工业产值常年稳居全国首位，全年黄金提货量约占上海黄 金交易所的七成，周大生（002867）、周六福等企业享誉全国。家具行业作为重要的研发设计、生产和 出口基地，孕育了左右家私、CBD家居、雅兰床垫等知名品牌。此外，深圳中高端眼镜产量约占全球 一半，钟表领域拥有7家中国"十强企业"，获誉"中国钟表之都"。 平原表示，接下来，深圳将充分发挥创新资源丰富、产 ...

在国内生物医药产业向创新化、多元化升级的浪潮中，长春高新技术产业（集团）股份有限公司（以下 简称"长春高新"）凭借对细分赛道的精准把控，勾勒出生长激素、多元商业化创新产品、新药"出海"授 权"三驾马车"并驾齐驱的全新格局。 今年9月份，长春高新旗下核心子公司长春金赛药业有限责任公司（以下简称"金赛药业"）与丹麦ALK- AbellóA/S公司（以下简称"ALK"）达成变应原特异性免疫治疗（AIT，俗称脱敏治疗）产品合作，将在 中国联合开发并商业化ALK的屋尘螨（HDM）变应原特异性免疫治疗产品，并获得ALK自主开发的3款 产品在中国大陆范围内的独家代理权益。 "脱敏，是我们全力进军免疫与呼吸领域的关键一步，是公司未来重要的业务增长点。未来，金赛药业 力争跻身中国呼吸领域第一梯队。"长春高新总经理，金赛药业创始人、总经理、首席科学家金磊对 《证券日报》记者表示。 在竞争激烈的生物医药领域，如何通过研发创新实现攻势突破、通过多元化与资本运作稳固防线、通过 国际化布局实现护城河延展，是长春高新面临的三道命题。近日，《证券日报》记者走进长春高新，探 寻公司攻与守的博弈之道。 创新为本 筑牢发展基石 创新研发是企业生存 ...

Core Viewpoint - The company潮宏基 is pursuing an IPO in Hong Kong amid a rising trend in gold consumption and investment, marking it as the first company in the domestic gold jewelry industry to attempt an "A+H" listing [1] Group 1: Financial Performance -潮宏基 has shown rapid revenue growth, with projected revenues of approximately 43.64 billion, 58.36 billion, 64.52 billion, and 40.62 billion from 2022 to the first half of 2025, with a net profit of 3.33 billion in the first half of 2025 [1][3] - Despite revenue growth, the company's gross margin has been under pressure, declining from 29.3% in 2022 to 22.6% in 2025, with a slight recovery to 23.1% in the first half of 2025, which is lower compared to competitors like周大福 and周大生 [1][3] Group 2: Business Model and Challenges -潮宏基 has shifted from a self-operated model to a franchise model to expand market share, resulting in 1,542 stores by mid-2025, with 86.9% being franchise stores [3] - The franchise model has led to lower gross margins, with franchise channel gross margin at 16.6% compared to 35.3% for self-operated channels in the first half of 2025, impacting overall profitability [3][5] - The company is adjusting its product mix to focus on "fashion jewelry" and "classic gold jewelry," with the revenue share of gold jewelry increasing from 32.6% in 2022 to 44.6% in the first half of 2025, further squeezing overall gross margins [5] Group 3: Financial Risks -潮宏基's trade receivables have increased from approximately 266 million in 2022 to 370 million in the first half of 2025, posing potential cash flow risks if collection management is not handled properly [5] Group 4: Strategic Moves and Market Sentiment -潮宏基's second-largest shareholder,东冠集团, announced plans to reduce its stake by up to 3%, raising concerns about market confidence in the company's long-term transformation amid a strategic shift and IPO preparations [9] - The company is facing legal challenges from luxury brands like宝格丽 and卡地亚, which could impact its international expansion plans and brand image [12][13]

当地时间9月27日上午11点，美团旗下国际外卖品牌Keeta正式在阿联酋迪拜启动运营——这是Keeta继8 月上线卡塔尔、9月上线科威特后，40天内开拓的第三个中东国家外卖市场。阿联酋也成为美团国际化 业务在中东海湾地区的第四个战略落点。 ▲ Keeta骑手正在科威特街头送餐。 围绕"零售+科技"战略，近年来，美团在全球更多新市场里实现了即时零售服务的多场景、多业态协同 发展。 keeta l Dubai - United Arab Emir... ∨ 9, 11 Q Burgers Enjoy 4 Vouchers! Order Now! SAVE UP TO 50% off 30% 40% off Max AED 50 Max AED 40 Max AED AED Free delivery · Unlimited (1 Fast food Arabic Beverages Desserts Indian Popular Brands > DUNKIN' Popeyes � Offers Free Delivery Sort by > Under 30 min Papa Murphy's Pizza Fa ...

Core Viewpoint - Heng Rui Pharmaceutical is positioned as a leading domestic innovative pharmaceutical company, focusing on R&D, production, and promotion of high-quality drugs, with significant growth potential despite market concerns about future growth [1][2]. Group 1: Company Overview - Established in 1970, Heng Rui specializes in oncology, metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [1]. - The company has achieved leading performance and market capitalization in the domestic pharmaceutical sector [1]. Group 2: Market Dynamics - The peak impact of centralized procurement for generic drugs has passed, with only two products, Sevoflurane and Iodine-131, still facing procurement risks, which are expected to have limited impact [1]. - The company is actively promoting its formulation export business, which is anticipated to become a new growth point for its generic drug operations [1]. Group 3: Innovation and R&D - Since 2021, the company has seen a peak in the commercialization of its innovative pipeline, with a total of 11 products expected to be approved from 2021 to 2024, including drugs with significant market potential [2]. - The projected revenue from innovative drugs for 2025-2027 is expected to reach 15.3 billion, 19.2 billion, and 24 billion yuan, with a compound annual growth rate exceeding 20% from 2024 to 2027 [2]. Group 4: Internationalization - The company is enhancing its internationalization efforts, having initiated 20 clinical trials overseas by mid-2025, and is actively seeking partnerships with leading global pharmaceutical companies [2]. - The licensing of innovative drugs to external parties is expected to become a regular business practice, significantly enhancing the company's global influence and industry recognition [2]. Group 5: Financial Projections - Projected revenues for Heng Rui Pharmaceutical from 2025 to 2027 are estimated at 34.573 billion, 37.735 billion, and 43.314 billion yuan, with year-on-year growth rates of 23.5%, 9.1%, and 14.8% respectively [3]. - The expected net profit attributable to the parent company for the same period is forecasted to be 9.999 billion, 11.109 billion, and 12.821 billion yuan, with growth rates of 57.8%, 11.1%, and 15.4% respectively [3].

Investment Rating - The report assigns a "Strong Buy" rating to the company, Heng Rui Medicine [1][9]. Core Views - Heng Rui Medicine is positioned as a leading domestic innovative pharmaceutical company, leveraging innovation and internationalization to achieve rapid growth. The company is expected to see significant revenue from external licensing, which is anticipated to become a normalized business practice [6][9]. Financial Projections - Total revenue is projected to reach 27,985 million in 2024, with a year-on-year growth rate of 22.6%. By 2027, revenue is expected to grow to 43,314 million, reflecting a growth rate of 14.8% [2]. - Net profit attributable to shareholders is forecasted to be 6,337 million in 2024, increasing to 12,821 million by 2027, with growth rates of 47.3% and 15.4% respectively [2]. - Earnings per share are expected to rise from 0.95 in 2024 to 1.93 in 2027 [2]. Company Overview - Heng Rui Medicine, established in 1970, focuses on the research, production, and promotion of high-quality drugs, particularly in oncology, metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [6][13]. - The company has experienced significant growth, with revenue increasing from 364 million in 1998 to 27,985 million in 2024, representing a compound annual growth rate of 18% [13]. Market Position and Growth Potential - Despite concerns about future growth, the company has substantial room for expansion based on the proportion of innovative drug revenue, market share in covered areas, and international revenue [14][15]. - The company’s innovative drug revenue is projected to grow significantly, with estimates of 153 billion, 192 billion, and 240 billion for the years 2025 to 2027, respectively, indicating a compound annual growth rate exceeding 20% [8][9]. Internationalization and Licensing - The company is making strides in internationalization, having initiated 20 clinical trials overseas by mid-2025. External licensing is expected to become a regular business practice, enhancing the company's global influence [6][9]. - Revenue from external licensing is projected to reach 61.1 billion in 2025, with 19.5 billion confirmed in the first half of 2025 [9]. Risk Mitigation and Stability - The peak impact of centralized procurement on the company’s generic drug business has passed, with current risks being minimal. The company is also actively pursuing export opportunities for its formulations, which are expected to become new growth points [6][8][41].

Core Viewpoint - Heng Rui Medicine is positioned as a leading domestic innovative pharmaceutical company, focusing on research, production, and promotion of high-quality drugs, with significant growth potential driven by innovation and internationalization [3][4]. Group 1: Company Overview - Established in 1970, Heng Rui Medicine specializes in oncology, metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [3]. - The company has achieved leading performance and market capitalization in the domestic pharmaceutical sector, despite concerns about future growth [3]. Group 2: Market Dynamics - The peak impact of centralized procurement for generic drugs has passed, with only two products, Sevoflurane and Iodine-131, still facing procurement risks, which are expected to have limited effects [3][4]. - Heng Rui is actively promoting its formulation export business, which is anticipated to become a new growth point for its generic drug operations [3]. Group 3: Innovation and R&D - From 2021 to 2024, Heng Rui is expected to receive approvals for 11 innovative products, including promising drugs like Hecuqipar and Darsylin [4]. - The company’s innovative drug revenue is projected to reach 15.3 billion, 19.2 billion, and 24 billion yuan in 2025, 2026, and 2027 respectively, with a compound annual growth rate exceeding 20% from 2024 to 2027 [4]. Group 4: Internationalization Strategy - Heng Rui's internationalization has evolved from initial formulation exports to overseas clinical trials and licensing agreements, enhancing its global influence [4]. - By mid-2025, the company has initiated 20 clinical trials overseas and is seeking collaborations with leading global pharmaceutical companies [4]. Group 5: Financial Projections - Revenue projections for Heng Rui are 34.57 billion, 37.73 billion, and 43.31 billion yuan for 2025, 2026, and 2027, reflecting year-on-year growth rates of 23.5%, 9.1%, and 14.8% respectively [5]. - The net profit attributable to the parent company is expected to be 9.999 billion, 11.109 billion, and 12.821 billion yuan for the same years, with growth rates of 57.8%, 11.1%, and 15.4% respectively [5].

在25日举行的"高质量完成'十四五'规划"发布会上，国家广播电视总局副局长韩冬说，我国微短剧近年来蓬勃发展，迅速成为 新大众文艺的重要业态。广电部门一手抓繁荣、一手抓管理，推动微短剧行业健康稳定向上发展，今年市场规模有望在去年达 到500亿元的基础上，实现更大突破。跟随海报一起来看看。 新华社权威速览 ·非凡 加大扶持力度 新华社权威速览 ·非凡 促进规范管理 建立微短剧分类分层管理机制 正在制订《微短剧管理办法》 开展专项治理和常态化监管 对群众反映强烈的问题 如"雷人"剧情"霸总"人设等 及时进行纠偏 新华社权威速览 ·非凡' 精品化、大众化、国 加强选题指导、创作扶持 组织实施"微短剧+"行动计划 开展"跟着微短剧来学法" "微短剧里看非遗"等活动 指导各地加大对微短剧的扶持力度 推动精品化 打造更多讴歌奋斗人生 反映时代风貌的精品佳作 推动大众化 激发微短剧作为新大众文艺的创新创造活力 推动国际化 鼓励微短剧扩大国际交流与传播 统筹：曹建礼 制作：任彦逸 策划：令伟家 ...

Group 1 - The core viewpoint of the article is the introduction of a regulatory framework for micro-short dramas in China, aimed at promoting healthy development and addressing public concerns regarding content quality and appropriateness [1] - The National Radio and Television Administration is developing a management approach for micro-short dramas, which will include a classification and layered management mechanism to ensure orderly development [1] - There will be ongoing special governance and regular supervision to address issues such as inappropriate storylines and sensational titles, ensuring timely corrections [1] Group 2 - Future initiatives will focus on three main directions: promoting quality content, encouraging public participation in creation, and expanding international exchange and dissemination of micro-short dramas [1] - The emphasis on quality will involve enhancing creative guidance and optimizing resource allocation to support the production of high-quality works that reflect contemporary life and values [1] - The push for public engagement aims to stimulate innovation and creativity in micro-short dramas as a new form of popular art [1]

Group 1: Achievements in Broadcasting and Network Audiovisual Development - China has become a major player in broadcasting and network audiovisual sectors, with over 1 billion users across various platforms including cable TV, IPTV, and internet TV, and 1.09 billion network audiovisual users [1] - Since the beginning of the 14th Five-Year Plan, over 1,500 TV dramas, more than 3,500 animated films, and over 350,000 hours of documentaries have been produced [1] - The total revenue of the broadcasting and audiovisual service industry is projected to reach 1.49 trillion yuan in 2024, marking a 61.96% increase from the end of the 13th Five-Year Plan [1] Group 2: Development Direction of Micro Short Dramas - The micro short drama sector is experiencing rapid growth, with user numbers reaching 696 million by July this year, and the market size expected to exceed 50 billion yuan [2] - The industry is focusing on three main directions: promoting high-quality content, encouraging public participation in creation, and expanding international exchanges [5] - A "Micro Short Drama+" action plan has been implemented to diversify themes and enhance the quality of micro short dramas [2] Group 3: Regulatory and Management Measures - The National Radio and Television Administration is establishing a classification and tiered management system for micro short dramas to ensure orderly development [2] - Ongoing efforts include addressing public concerns regarding problematic content and implementing a regulatory framework to support the healthy growth of the industry [3][5] - Measures to improve user experience include deploying 10 million micro set-top boxes and simplifying remote control operations across various platforms [6][7]